This is the Vocab24 daily quiz of 6 September 2025, the same 30 questions the app served that day, on the day's vocabulary and editorial. One mark for a right answer, minus 0.25 for a wrong one; the explanation opens as soon as you tap.
Out of the given alternatives select the alternative which best expresses the meaning of given word.
Gradually
Out of the given alternatives select the alternative which best expresses the meaning of given word.
Narrative
Out of the given alternatives select the alternative which best expresses the meaning of given word.
Rejuvenation
Out of the given alternatives select the alternative which best expresses the meaning of given word.
Defeat
Out of the given alternatives select the word opposite in meaning to the given word.
Invasion
Out of the given alternatives select the word opposite in meaning to the given word.
Exhibition
Out of the given alternatives select the word opposite in meaning to the given word.
Prominence
Out of the given alternatives select the word opposite in meaning to the given word.
Confronted
Out of given alternatives, choose the word which can be substituted for the given words/ sentence.
Moving, changing, or developing by fine or often imperceptible degrees.
Out of given alternatives, choose the word which can be substituted for the given words/ sentence.
Having been beaten in a battle or other contest.
Out of given alternatives, choose the word which can be substituted for the given words/ sentence.
An instance of invading a country or region with an armed force.
Out of given alternatives, choose the word which can be substituted for the given words/ sentence.
Come face to face with (someone) with hostile or argumentative intent.
A statement with one blank is given below. Choose the set of words from the given options which can be used to fill the given blank.
The sun rises ____ the east.
Explanation: The preposition used along with 'rises' is in.
A statement with one blank is given below. Choose the set of words from the given options which can be used to fill the given blank.
Alcohol acts ____ the brain.
Explanation: 'acts on' means take action against something. The sentence means that 'alcohol' take action against the 'brain'.
A statement with one blank is given below. Choose the set of words from the given options which can be used to fill the given blank.
Joey ____ from the vacation just now.
Explanation: Solution: The word 'has' can be used to express possession: She has a wonderful dress. <br> 'Has been' is a present progressive tense verb. It implies anything that started in the past and is still going on or progressing. <br> The present perfect tense is used with the word 'had.' Had is the past perfect tense form of the verb 'to have,' which can also be used as an auxiliary verb.
Out of given alternatives select the option which best expresses the meaning of given idiom/ phrase.
When he heard that he had once again not been selected he lost heart.
Explanation: lost heart: having lost confidence or enthusiasm.
Out of given alternatives select the option which best expresses the meaning of given idiom/ phrase.
He was undecided. He let the grass grow under his feet.
Explanation: let the grass grow under his feet: to be inactive; to do nothing.
Out of given alternatives select the option which best expresses the meaning of given idiom/ phrase.
Although he has failed in the written examination, he is using backstairs influence to get the job.
Explanation: Backstairs influence: influence from a source that is secret.
Out of given alternatives select the word which is correctly spelt.
Choose the correct spelling.
Out of given alternatives select the word which is correctly spelt.
Choose the correct spelling.
Out of given alternatives select the word which is correctly spelt.
Choose the correct spelling.
Out of given alternatives select the word which is correctly spelt.
Choose the correct spelling.
Which of phrases given below each sentence should replace the phrase printed in bold type to make the grammatically correct? If the sentence is correct as it is, mark 'd' as the answer.
(a) He says that/ (b) he reads novels/ (c) to pass away the time./ (d) No error.
Explanation: to pass the time
Which of phrases given below each sentence should replace the phrase printed in bold type to make the grammatically correct? If the sentence is correct as it is, mark 'd' as the answer.
(a) Obviously the state of affairs/ (b) is known to the inner cabinet members/ (c) who reacts unfavourably to it/ (d) No error.
Explanation: who react
Which of phrases given below each sentence should replace the phrase printed in bold type to make the grammatically correct? If the sentence is correct as it is, mark 'd' as the answer.
(a) No sooner did the teacher/ (b) enter the class room/ (c) the students got up./ (d) No error.
Explanation: than the student
Directions: Read the following passage to answer the given questions based on it. Some words/phrases are printed in bold to help you locate them while answering some of the questions. <br><br> The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6 percent for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. India does not do any of this and faces many hurdles - diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-contiment specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry a decision must be taken quickly on the implementation of data protection laws. <br><br> India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bioequivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator's data to approve the competitor's product. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same-the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator's intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost. <br><br> The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Effective 2005, Indian companies can no longer copy patent-protected foreign drugs. Some negate the necessity to make data exclusivity a law. They argue that the advocates of making it a law, the MNCs, want the data to be protected absolutely for a period of 5 years. However, in case certain drugs are not available or unaffordable, should the government for the common good not be able to exercise power to get another company to make such drugs?
Which of the following is a reason for India's continuing battle with commonplace diseases?
Explanation: ... Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-continent specific diseases as there are more profits and public interest in lifestyle drugs such as obesity ... <br><br> The above sentence from the latter half of the first paragraph of the passage clearly states the reason for India's continuing battle with commonplace diseases. <br><br> Option E hence is the correct answer here.
Directions: Read the following passage to answer the given questions based on it. Some words/phrases are printed in bold to help you locate them while answering some of the questions. <br><br> The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6 percent for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. India does not do any of this and faces many hurdles - diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-contiment specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry a decision must be taken quickly on the implementation of data protection laws. <br><br> India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bioequivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator's data to approve the competitor's product. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same-the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator's intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost. <br><br> The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Effective 2005, Indian companies can no longer copy patent-protected foreign drugs. Some negate the necessity to make data exclusivity a law. They argue that the advocates of making it a law, the MNCs, want the data to be protected absolutely for a period of 5 years. However, in case certain drugs are not available or unaffordable, should the government for the common good not be able to exercise power to get another company to make such drugs?
Which of the following is/are TRUE in the context of the passage? <br> 1. Countries like China prefer to outsource research to avoid exorbitant cost of research at home. <br> 2. Multinational pharma companies are pressurizing India to have product patent laws. <br> 3. The Indian pharmaceutical industry is booming.
Explanation: ... Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way ... <br> The 1st statement is not true in the context of the passage because the above sentence from the 1st paragraph of the passage clearly suggests that China facilitates foreign research to make up the unavailability of scientists in its country. Cost factor hasn't been mentioned in the passage at all. <br> The 2nd statement holds true. Kindly refer to the last paragraph of the passage. <br> The 3rd statement also holds true. Kindly refer to the 1st sentence of the 1st paragraph of the passage.
Directions: Read the following passage to answer the given questions based on it. Some words/phrases are printed in bold to help you locate them while answering some of the questions. <br><br> The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6 percent for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. India does not do any of this and faces many hurdles - diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-contiment specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry a decision must be taken quickly on the implementation of data protection laws. <br><br> India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bioequivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator's data to approve the competitor's product. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same-the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator's intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost. <br><br> The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Effective 2005, Indian companies can no longer copy patent-protected foreign drugs. Some negate the necessity to make data exclusivity a law. They argue that the advocates of making it a law, the MNCs, want the data to be protected absolutely for a period of 5 years. However, in case certain drugs are not available or unaffordable, should the government for the common good not be able to exercise power to get another company to make such drugs?
According to the passage, what is the main purpose of data protection laws?
Explanation: The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Option C is the correct answer here.
Directions: Read the following passage to answer the given questions based on it. Some words/phrases are printed in bold to help you locate them while answering some of the questions. <br><br> The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6 percent for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. India does not do any of this and faces many hurdles - diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-contiment specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry a decision must be taken quickly on the implementation of data protection laws. <br><br> India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bioequivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator's data to approve the competitor's product. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same-the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator's intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost. <br><br> The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Effective 2005, Indian companies can no longer copy patent-protected foreign drugs. Some negate the necessity to make data exclusivity a law. They argue that the advocates of making it a law, the MNCs, want the data to be protected absolutely for a period of 5 years. However, in case certain drugs are not available or unaffordable, should the government for the common good not be able to exercise power to get another company to make such drugs?
Which of the following measures has Korea taken to be competitive in the pharma industry?
Explanation: ... Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. ... Clearly option E is the correct answer.
Directions: Read the following passage to answer the given questions based on it. Some words/phrases are printed in bold to help you locate them while answering some of the questions. <br><br> The Indian pharma industry is flourishing overseas, touching almost every part of the world. With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. Having a competitive edge is, one thing and maintaining it is another. Canada provides tax benefits up to 6 percent for research carried out within the country. Others like Korea and China without a large pool of scientists make up by facilitating foreign research in every conceivable way. India does not do any of this and faces many hurdles - diseases that it has been inflicted with since independence like Malaria and TB while Indian companies have only focused on reverse engineering blockbuster drugs from MNCs, overseas scientists have displayed little interest in researching sub-contiment specific diseases as there are more profits and public interest in lifestyle drugs such as obesity which in turn fund their research. In the interest of Indian research industry a decision must be taken quickly on the implementation of data protection laws. <br><br> India is one of the few countries where data exclusivity provisions are not prevalent. Data protection is a contentious issue, wholly debated by the government and the industry. A pharma company wishing to market a drug is required to submit data to the drug controller to show that the drug is both effective and safe. The first (originator) company that makes the application for marketing approval has to submit its data relating to the clinical trials to the drug controller, who once satisfied that the drug is safe and effective will register it. Another drug company wishing to market the same drug only requires to show a bioequivalence company. Thus, as per the prevailing laws, the regulator in India can rely on an innovator's data to approve the competitor's product. While the system in general is responsible for maintaining the necessary secrecy, it is not accountable for the same-the competitor gets an unfair advantage over the innovator even when he is clandestinely abusing an innovator's intellectual property. Consequently research-based pharma companies are being forced to undertake vital clinical trials abroad. Huge expenditures are incurred overseas, draining precious foreign exchange when this could be done at home at a fraction of the cost. <br><br> The product patent law protections required by the TRIPS agreement and brought about by the 2005 amendment to the Patent Act require India to protect undisclosed test data from disclosure and unfair commercial use by competitors. Effective 2005, Indian companies can no longer copy patent-protected foreign drugs. Some negate the necessity to make data exclusivity a law. They argue that the advocates of making it a law, the MNCs, want the data to be protected absolutely for a period of 5 years. However, in case certain drugs are not available or unaffordable, should the government for the common good not be able to exercise power to get another company to make such drugs?
Which of the following is/are India's strengths in drug discovery and research? <br> 1. Relaxed patent laws<br> 2. Reverse engineering of foreign blockbuster drugs<br> 3. Incentives to foreign companies researching sub-continent diseases.
Explanation: ... With low cost, speed and high quality advantage, India is gearing up to become the hub for contract research and manufacturing. ... <br> It's evident from the 2nd statement of the 1st paragraph of the passage that India's strengths in drug discovery and research are low cost, speed and high quality. <br> Option E hence is the correct answer.
One Prime for the website and the app, same login. Videos play in the app.
30 questions in 15 minutes, All India rank, streak and explanations. Free: play it here after logging in, or in the app.
Free. Mobile number + OTP, no password.
